NeoImmuneTech Statistics
Total Valuation
NeoImmuneTech has a market cap or net worth of KRW 139.40 billion. The enterprise value is 112.86 billion.
Important Dates
The next estimated earnings date is Friday, March 19, 2027.
| Earnings Date | Mar 19, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoImmuneTech has 98.87 million shares outstanding. The number of shares has increased by 220.31% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 98.87M |
| Shares Change (YoY) | +220.31% |
| Shares Change (QoQ) | -6.42% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | n/a |
| Float | 92.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.11 |
| PB Ratio | 3.00 |
| P/TBV Ratio | 5.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.01, with a Debt / Equity ratio of 0.25.
| Current Ratio | 2.01 |
| Quick Ratio | 1.89 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.11 |
Financial Efficiency
Return on equity (ROE) is -40.77% and return on invested capital (ROIC) is -19.08%.
| Return on Equity (ROE) | -40.77% |
| Return on Assets (ROA) | -16.41% |
| Return on Invested Capital (ROIC) | -19.08% |
| Return on Capital Employed (ROCE) | -43.08% |
| Weighted Average Cost of Capital (WACC) | 8.29% |
| Revenue Per Employee | 126.97M |
| Profits Per Employee | -439.34M |
| Employee Count | 42 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NeoImmuneTech has paid 37.43 million in taxes.
| Income Tax | 37.43M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.46% in the last 52 weeks. The beta is 0.60, so NeoImmuneTech's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | -49.46% |
| 50-Day Moving Average | 1,777.40 |
| 200-Day Moving Average | 2,238.96 |
| Relative Strength Index (RSI) | 30.29 |
| Average Volume (20 Days) | 103,336 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NeoImmuneTech had revenue of KRW 6.60 billion and -22.85 billion in losses. Loss per share was -179.07.
| Revenue | 6.60B |
| Gross Profit | 4.40B |
| Operating Income | -20.63B |
| Pretax Income | -22.81B |
| Net Income | -22.85B |
| EBITDA | -17.77B |
| EBIT | -20.63B |
| Loss Per Share | -179.07 |
Full Income Statement Balance Sheet
The company has 38.11 billion in cash and 11.57 billion in debt, with a net cash position of 26.55 billion or 268.51 per share.
| Cash & Cash Equivalents | 38.11B |
| Total Debt | 11.57B |
| Net Cash | 26.55B |
| Net Cash Per Share | 268.51 |
| Equity (Book Value) | 46.50B |
| Book Value Per Share | 1,343.31 |
| Working Capital | 21.09B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -17.22 billion and capital expenditures -91.78 million, giving a free cash flow of -17.32 billion.
| Operating Cash Flow | -17.22B |
| Capital Expenditures | -91.78M |
| Depreciation & Amortization | 2.86B |
| Net Borrowing | -750.94M |
| Free Cash Flow | -17.32B |
| FCF Per Share | -175.15 |
Full Cash Flow Statement Margins
| Gross Margin | 66.61% |
| Operating Margin | -312.48% |
| Pretax Margin | -345.46% |
| Profit Margin | n/a |
| EBITDA Margin | -269.19% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NeoImmuneTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -220.31% |
| Shareholder Yield | -220.31% |
| Earnings Yield | -12.70% |
| FCF Yield | -12.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on May 15, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | May 15, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
NeoImmuneTech has an Altman Z-Score of -0.59 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.59 |
| Piotroski F-Score | 2 |